Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

Core Insights - Keros Therapeutics, Inc. announced additional data from its Phase 1 clinical trial of rinvatercept (KER-065), highlighting its potential in treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [1][2] Clinical Development - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving healthy adult male volunteers, focusing on safety, tolerability, and pharmacokinetics of rinvatercept [2] - Initial topline data from the trial was reported in March 2025, indicating that rinvatercept was well-tolerated across all evaluated dose levels, with no serious adverse events reported [3] Mechanism of Action - Rinvatercept demonstrated effects consistent with activin and myostatin inhibition, leading to increased muscle mass, decreased fat mass, and improved bone mineral density [3] - Proteomic analysis indicated that rinvatercept mitigates fibrosis and inflammation, aligning with preclinical observations of its anti-fibrotic and anti-inflammatory properties [4] Product Overview - Rinvatercept is a novel ligand trap designed to inhibit the biological effects of myostatin and activin A, which negatively regulate muscle and bone mass, aiming to enhance muscle regeneration and overall skeletal health [5][8] - The company is also developing elritercept for treating cytopenias in patients with myelodysplastic syndrome and myelofibrosis [8]